IPI Score
Young patient, localized disease
Did our AI summary help? Let us know.
Evidence-based calculations Used in clinical settings worldwide Regular monitoring recommended
Ready to run the numbers?
Why: This calculation helps assess important health parameters for clinical and personal wellness tracking.
How: Enter your values above and the calculator will apply validated formulas to compute your results.
Run the calculator when you are ready.
✅ Very Good Prognosis
Young patient, localized disease
Click to load
👍 Good Prognosis
Low-intermediate risk
Click to load
⚠️ Intermediate Risk
High-intermediate risk patient
Click to load
🔴 High Risk
Poor prognosis patient
Click to load
👴 Elderly Patient
Geriatric oncology considerations
Click to load
🧬 Double-Hit Lymphoma
High-risk molecular subtype
Click to load
🔬 ABC/Non-GCB Type
Activated B-cell subtype
Click to load
📏 Bulky Disease
Large tumor burden
Click to load
Patient Information
Disease Staging
For informational purposes only — not medical advice. Consult a healthcare professional before acting on results.
🏥 Health Facts
— WHO
— CDC
Understanding Diffuse Large B-Cell Lymphoma
DLBCL is the most common type of non-Hodgkin lymphoma, accounting for about 30-40% of all cases. It is an aggressive lymphoma but is potentially curable with immunochemotherapy. The International Prognostic Index (IPI) helps stratify patients into risk groups to guide treatment decisions.
4-year OS
IPI: 0-1
4-year OS
IPI: 2
4-year OS
IPI: 3
4-year OS
IPI: 4-5
International Prognostic Index (IPI)
| Risk Factor | Adverse (1 point) | Favorable (0 points) |
|---|---|---|
| Age | >60 years | ≤60 years |
| ECOG Performance Status | ≥2 | 0-1 |
| LDH Level | Elevated (>ULN) | Normal |
| Ann Arbor Stage | III-IV | I-II |
| Extranodal Sites | >1 site | 0-1 sites |
Treatment Approach
Standard Treatment: R-CHOP
- • Rituximab - anti-CD20 antibody
- • Cyclophosphamide - alkylating agent
- • Doxorubicin (Hydroxydaunorubicin)
- • Vincristine (Oncovin)
- • Prednisone
- • Typically 6 cycles, every 21 days
High-Risk Options
- • DA-EPOCH-R - dose-adjusted regimen
- • CAR-T cell therapy (relapsed/refractory)
- • Polatuzumab vedotin combinations
- • Autologous stem cell transplant
- • Clinical trials
Ann Arbor Staging System
Stage I
Single lymph node region or single extranodal site (IE)
Stage II
≥2 lymph node regions on same side of diaphragm, or localized extranodal (IIE)
Stage III
Lymph node regions on both sides of diaphragm, ± spleen (IIIS) or extranodal (IIIE)
Stage IV
Diffuse or disseminated involvement of ≥1 extranodal organs (liver, BM, lung, etc.)
Modifiers: A = no B symptoms; B = fever, night sweats, weight loss >10%; X = bulky disease (>10 cm or mediastinal mass ratio >1/3); E = extranodal extension
ECOG Performance Status Scale
| Grade | Description | Karnofsky Equivalent |
|---|---|---|
| 0 | Fully active, no restrictions | 100% |
| 1 | Restricted in strenuous activity, ambulatory and able to do light work | 80-90% |
| 2 | Ambulatory, capable of self-care, unable to work, up >50% of waking hours | 60-70% |
| 3 | Limited self-care, confined to bed/chair >50% of waking hours | 40-50% |
| 4 | Completely disabled, totally confined to bed/chair, no self-care | 10-30% |
Molecular and Genetic Features
Cell of Origin (COO)
GCB (Germinal Center B-cell)
~35-40% of cases. Better prognosis, 75% 5-year OS with R-CHOP.
ABC (Activated B-cell)
~30-35% of cases. Worse prognosis, 45% 5-year OS. May benefit from targeted agents.
Unclassifiable
~10-15% of cases. Intermediate prognosis.
High-Risk Genetic Features
Double-Hit Lymphoma
MYC + BCL2 or BCL6 rearrangements. 5-10% of DLBCL. Very poor prognosis.
Triple-Hit Lymphoma
MYC + BCL2 + BCL6 rearrangements. Extremely poor prognosis.
Double-Expresser
MYC and BCL2 protein overexpression without rearrangement. Intermediate prognosis.
CNS Prophylaxis Considerations
High-Risk Features for CNS Involvement
- • IPI score 4-5 (CNS-IPI >4)
- • Double-hit lymphoma
- • Testicular involvement
- • Kidney or adrenal involvement
- • Breast involvement
- • High LDH (>3× ULN)
- • Multiple extranodal sites (>2)
- • Bone marrow involvement
Prophylaxis options: Intrathecal methotrexate (IT MTX) × 4-6 doses, or high-dose IV methotrexate (3-3.5 g/m²) × 2-4 cycles interdigitated with R-CHOP.
Post-Treatment Surveillance
Years 1-2
- • H&P every 3-6 months
- • Labs (CBC, LDH) every 3-6 months
- • CT scan every 6 months × 2 years
- • PET/CT if concern for recurrence
Years 3-5
- • H&P every 6-12 months
- • Labs annually
- • CT scan annually or as indicated
- • Cardiac monitoring if anthracycline
Beyond 5 Years
- • Annual H&P
- • Labs as indicated
- • Screen for secondary malignancies
- • Long-term survivorship care
Related Calculators
NLR Calculator - Neutrophil-to-Lymphocyte Ratio
Calculate and interpret the Neutrophil-to-Lymphocyte Ratio (NLR), a biomarker of systemic inflammation used to assess infection severity, cardiovascular...
healthAllowable Blood Loss Calculator
Calculate maximum allowable blood loss for surgical planning using Nadler equation and transfusion thresholds.
healthBlood Donor Eligibility Calculator
Screen blood donor eligibility based on hemoglobin, weight, age, and health criteria per Red Cross guidelines.
healthBlood Type Inheritance Calculator
Predict child blood type probabilities based on parental genetics using Punnett square analysis.
healthBlood Volume Calculator
Estimate total blood volume using Nadler equation and weight-based methods with plasma and red cell breakdown.
healthDIC Syndrome Calculator (ISTH Score)
Calculate ISTH DIC score for diagnosis of disseminated intravascular coagulation with pregnancy modification.
health